Company / Working Capital
ALNYLAM PHARMACEUTICALS, INC. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$2.6B
FY2025
5-year range
$1.9B / $2.6B
FY2021-FY2025
Trend
+22.5%
vs FY2024
Sector context
#17 of 213
Health Care
What the data says
Among 213 Health Care companies, ALNYLAM PHARMACEUTICALS, INC. is in the top 8% for working capital. Working Capital has increased for 3 consecutive years, from $1.9B in FY2022 to $2.6B in FY2025.
Based on SEC 10-K filings.
$2.6B in FY2025 with a 5-year CAGR of +5.0%. Top quartile in the Health Care sector.
Improved from $2.0B to $2.6B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +10.3%
- 5-Year CAGR
- +5.0%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 213This company $2.6B Sector average $934.6M
▼
+176.5% above sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s working capital has grown for 3 consecutive years.
- 5-year CAGR of +5.0%, indicating consistent growth.
- In FY2025, working capital increased 22.5% year-over-year.
- Ranks #17 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.6B | +22.5% |
| FY2024 | $2.1B | +4.7% |
| FY2023 | $2.0B | +4.7% |
| FY2022 | $1.9B | -8.9% |
| FY2021 | $2.1B | +4.1% |
| FY2020 | $2.0B | +48.9% |
| FY2019 | $1.4B | +33.5% |
| FY2018 | $1.0B | -37.0% |
| FY2017 | $1.6B | +200.0% |
| FY2016 | $540.2M | -48.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026